HK1208441A1 - Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists alx [24] - Google Patents
Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists alx [24]Info
- Publication number
- HK1208441A1 HK1208441A1 HK15108959.5A HK15108959A HK1208441A1 HK 1208441 A1 HK1208441 A1 HK 1208441A1 HK 15108959 A HK15108959 A HK 15108959A HK 1208441 A1 HK1208441 A1 HK 1208441A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- alx
- receptor agonists
- heptane derivatives
- bridged spiro
- fluorinated bridged
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168322 | 2012-05-16 | ||
| PCT/IB2013/053976 WO2013171694A1 (en) | 2012-05-16 | 2013-05-15 | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208441A1 true HK1208441A1 (en) | 2016-03-04 |
Family
ID=48699893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15108959.5A HK1208441A1 (en) | 2012-05-16 | 2015-09-14 | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists alx [24] |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9139524B2 (xx) |
| EP (1) | EP2850060B1 (xx) |
| JP (1) | JP6101789B2 (xx) |
| KR (1) | KR20150013285A (xx) |
| CN (1) | CN104321309B (xx) |
| AR (1) | AR091059A1 (xx) |
| AU (1) | AU2013261091B2 (xx) |
| BR (1) | BR112014028358A2 (xx) |
| CA (1) | CA2871336A1 (xx) |
| CL (1) | CL2014002918A1 (xx) |
| EA (1) | EA025264B1 (xx) |
| ES (1) | ES2595219T3 (xx) |
| HK (1) | HK1208441A1 (xx) |
| IL (1) | IL235660A0 (xx) |
| MA (1) | MA37618B1 (xx) |
| MX (1) | MX355221B (xx) |
| NZ (1) | NZ702971A (xx) |
| PH (1) | PH12014502465A1 (xx) |
| PL (1) | PL2850060T3 (xx) |
| SG (1) | SG11201406971WA (xx) |
| TW (1) | TWI579269B (xx) |
| WO (1) | WO2013171694A1 (xx) |
| ZA (1) | ZA201409249B (xx) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2814826C (en) | 2010-11-17 | 2019-02-12 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| WO2012077051A1 (en) | 2010-12-07 | 2012-06-14 | Actelion Pharmaceuticals Ltd | Hydroxylated aminotriazole derivatives as alx receptor agonists |
| WO2013171687A1 (en) | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| EP3022188B1 (en) | 2013-07-18 | 2017-06-07 | Actelion Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| JO3563B1 (ar) | 2014-05-13 | 2020-07-05 | Novartis Ag | مركبات وتركيبات لتحفيز تكوين الغضاريف |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| EA201792382A1 (ru) | 2015-05-27 | 2018-04-30 | Киорин Фармасютикал Ко., Лтд. | Производное мочевины или его фармакологически приемлемая соль |
| CN111233751B (zh) * | 2020-03-25 | 2021-02-02 | 丽水绿氟科技有限公司 | 一种3,3-二氟-4-氨基哌啶类化合物及其衍生物的制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002587A1 (en) | 1993-07-16 | 1995-01-26 | Merck & Co., Inc. | Substituted piperazinylcamphor derivatives as oxytocin antagonists |
| EP1492552A2 (en) | 2002-04-03 | 2005-01-05 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| JP2007508260A (ja) | 2003-10-09 | 2007-04-05 | アクテリオン ファマシューティカルズ リミテッド | 新規なテトラヒドロピリジン誘導体 |
| KR20060130064A (ko) | 2003-11-07 | 2006-12-18 | 아카디아 파마슈티칼스 인코포레이티드 | 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도 |
| TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| US7820699B2 (en) | 2005-04-27 | 2010-10-26 | Hoffmann-La Roche Inc. | Cyclic amines |
| JP2010522765A (ja) | 2007-03-28 | 2010-07-08 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物 |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| BRPI0821115A8 (pt) | 2007-12-18 | 2017-12-26 | Actelion Pharmaceuticals Ltd | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto |
| DK2432760T3 (da) * | 2009-05-18 | 2013-09-08 | Actelion Pharmaceuticals Ltd | Brokoblede spiro [2.4]-heptanderivater som alx-receptor og/eller fprl2-agonister |
| KR101444559B1 (ko) | 2009-06-09 | 2014-09-26 | 액테리온 파마슈티칼 리미티드 | 불화 아미노트리아졸 유도체 |
| CA2760887A1 (en) | 2009-06-12 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Oxazole and thiazole derivatives as alx receptor agonists |
| WO2011163502A1 (en) | 2010-06-24 | 2011-12-29 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| CA2814826C (en) * | 2010-11-17 | 2019-02-12 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| WO2012077051A1 (en) | 2010-12-07 | 2012-06-14 | Actelion Pharmaceuticals Ltd | Hydroxylated aminotriazole derivatives as alx receptor agonists |
| SI2649068T1 (sl) | 2010-12-07 | 2015-01-30 | Actelion Pharmaceuticals Ltd. | Derivati oksazolil-metiletra kot agonisti alx-receptorja |
| EP2731931A1 (en) | 2011-07-11 | 2014-05-21 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| WO2013171687A1 (en) | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| CN107714683A (zh) | 2013-03-06 | 2018-02-23 | 阿勒根公司 | 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途 |
| CA3133264A1 (en) | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
-
2013
- 2013-05-14 MA MA37618A patent/MA37618B1/fr unknown
- 2013-05-15 ES ES13731938.0T patent/ES2595219T3/es active Active
- 2013-05-15 MX MX2014013829A patent/MX355221B/es active IP Right Grant
- 2013-05-15 EA EA201401259A patent/EA025264B1/ru not_active IP Right Cessation
- 2013-05-15 AR ARP130101686 patent/AR091059A1/es unknown
- 2013-05-15 TW TW102117256A patent/TWI579269B/zh not_active IP Right Cessation
- 2013-05-15 CA CA2871336A patent/CA2871336A1/en not_active Abandoned
- 2013-05-15 SG SG11201406971WA patent/SG11201406971WA/en unknown
- 2013-05-15 US US14/401,769 patent/US9139524B2/en not_active Expired - Fee Related
- 2013-05-15 KR KR20147034766A patent/KR20150013285A/ko not_active Application Discontinuation
- 2013-05-15 NZ NZ702971A patent/NZ702971A/en not_active IP Right Cessation
- 2013-05-15 WO PCT/IB2013/053976 patent/WO2013171694A1/en active Application Filing
- 2013-05-15 PL PL13731938T patent/PL2850060T3/pl unknown
- 2013-05-15 BR BR112014028358-3A patent/BR112014028358A2/pt not_active IP Right Cessation
- 2013-05-15 JP JP2015512184A patent/JP6101789B2/ja not_active Expired - Fee Related
- 2013-05-15 AU AU2013261091A patent/AU2013261091B2/en not_active Ceased
- 2013-05-15 CN CN201380025040.5A patent/CN104321309B/zh not_active Expired - Fee Related
- 2013-05-15 EP EP13731938.0A patent/EP2850060B1/en not_active Not-in-force
-
2014
- 2014-10-28 CL CL2014002918A patent/CL2014002918A1/es unknown
- 2014-11-05 PH PH12014502465A patent/PH12014502465A1/en unknown
- 2014-11-12 IL IL235660A patent/IL235660A0/en unknown
- 2014-12-15 ZA ZA2014/09249A patent/ZA201409249B/en unknown
-
2015
- 2015-09-14 HK HK15108959.5A patent/HK1208441A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013261091B2 (en) | 2017-04-06 |
| EP2850060A1 (en) | 2015-03-25 |
| CN104321309A (zh) | 2015-01-28 |
| KR20150013285A (ko) | 2015-02-04 |
| EA201401259A1 (ru) | 2015-04-30 |
| SG11201406971WA (en) | 2014-11-27 |
| MA37618B1 (fr) | 2017-08-31 |
| PL2850060T3 (pl) | 2017-01-31 |
| AR091059A1 (es) | 2014-12-30 |
| AU2013261091A1 (en) | 2015-01-22 |
| MX2014013829A (es) | 2015-02-04 |
| NZ702971A (en) | 2016-09-30 |
| JP6101789B2 (ja) | 2017-03-22 |
| CL2014002918A1 (es) | 2015-02-06 |
| PH12014502465A1 (en) | 2014-12-22 |
| MA37618A1 (fr) | 2016-12-30 |
| US20150118258A1 (en) | 2015-04-30 |
| EP2850060B1 (en) | 2016-07-13 |
| TW201348198A (zh) | 2013-12-01 |
| CA2871336A1 (en) | 2013-11-21 |
| BR112014028358A2 (pt) | 2020-07-21 |
| EA025264B1 (ru) | 2016-12-30 |
| US9139524B2 (en) | 2015-09-22 |
| CN104321309B (zh) | 2016-06-22 |
| TWI579269B (zh) | 2017-04-21 |
| ZA201409249B (en) | 2016-09-28 |
| MX355221B (es) | 2018-04-10 |
| WO2013171694A1 (en) | 2013-11-21 |
| JP2015516463A (ja) | 2015-06-11 |
| ES2595219T3 (es) | 2016-12-28 |
| IL235660A0 (en) | 2015-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1208441A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists alx [24] | |
| HRP20200245T1 (hr) | Postupci za pripravu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina | |
| IL231949A0 (en) | History of [3,2,1]triazolo[5,4–d]pyrimidines as cannabinoid receptor 2 agonists | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| EP2848994A4 (en) | ACCESSORY AND BODY FOR TAKING APPARATUS | |
| EP2817295A4 (en) | SUBSTITUTED 5-AMINOTHIENO- [2,3-C-] PYRIDAZINE-6-CARBOXAMIDANALOGA AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINACETYLCHOLIN RECEPTOR M4 | |
| ZA201601726B (en) | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl | |
| PL2649068T3 (pl) | Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX | |
| EP2930403A4 (en) | PISTON RING | |
| ZA201701814B (en) | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 | |
| HK1213559A1 (zh) | 作為 受體激動劑的吡咯並 嘧啶衍生物 | |
| HK1202546A1 (en) | Novel adamantyl derivatives as cannabinoid receptor agonists | |
| HK1207379A1 (en) | 6-aminoindole derivatives as trp channel antagonists trp 6- | |
| ZA201407696B (en) | Azetidine derivatives as antiparasitic agents | |
| EP2851075A4 (en) | PREPARATION WITH 6,7-UNSATED 7-CARBAMOYLMORPHINANE DERIVATIVE | |
| IL236473B (en) | 1, 5-dihydro-2-pyrrole-one derivatives as cholecystokinin receptor ligands | |
| PL2814825T3 (pl) | Dihydrofuranowe pochodne azetydyny jako środki przeciwpasożytnicze | |
| EP2733395A4 (en) | PISTON RING | |
| HK1208028A1 (en) | Novel acetamide derivatives as trp channel antagonists trp | |
| HK1200821A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators gpbar1 12-16-- | |
| SG11201406582XA (en) | Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the | |
| GB201502644D0 (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists | |
| AU2012903933A0 (en) | Chaz's Knotchamacallit | |
| GB201204897D0 (en) | Optimob, an optical accessory attachment system | |
| GB201219053D0 (en) | Aleshba's oil |